期刊
MOLECULAR ONCOLOGY
卷 9, 期 8, 页码 1599-1611出版社
WILEY
DOI: 10.1016/j.molonc.2015.04.012
关键词
beta-catenin; CCL25; CCR9; Drug resistance; Pancreatic cancer
类别
资金
- Research Scholar Grant from the American Cancer Society [120687-RSG-11-070-01-TBE]
- City of Hope Comprehensive Cancer Center [P30 CA33572-27]
Elevated levels of chemoldne receptor CCR9 expression in solid tumors may contribute to poor patient prognosis. In this study, we characterized a novel CCR9-mediated pathway that promotes pancreatic cancer cell invasion and drug resistance, indicating that CCR9 may play a critical role in cancer progression through activation of beta-catenin. We noted that the CCL25/CCR9 axis in pancreatic cancer cells induced the activation of beta-catenin, which enhanced cell proliferation, invasion, and drug resistance. CCR9-mediated activation of beta-catenin and the resulting downstream effects were effectively inhibited by blockade of the PI3K/AKT pathway, but not by antagonism of Wnt. Importantly, we discovered that CCR9/CCL25 increased the lethal dose of gemcitabine, suggesting decreased efficacy of anti-cancer drugs with CCR9 signaling. Through in silico computational modeling, we identified candidate CCR9 antagonists and tested their effects on CCR9/beta-catenin regulation of cell signaling and drug sensitivity. When combined with gemcitabine, it resulted in synergistic cytotoxicity. Our results show that CCR9/beta-catenin signaling enhances pancreatic cancer invasiveness and chemoresistance, and may be a highly novel therapeutic target. (C) 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据